Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Get the next $AWH alert in real time by email

Interim CFO John Kallassy to Depart January 10

AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations.

Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses. He brings hands-on leadership experience in clinical diagnostics specializing in precision medicine and patient outcomes in oncology, rare diseases, infectious diseases, and drug development and preventative interventions. Prior to joining Aspira, Mr. Buhle served as Chief Commercial Officer at Biovision Diagnostics and Vice President of Sales, Americas for Congenica.

"I am excited and honored to join Aspira Women's Health and look forward to leading such a dedicated and passionate commercial team," said Mike Buhle, Aspira's SVP of Commercial Operations. "Together, we will continue to build on the momentum established, driving growth, and creating new opportunities. I believe that Aspira is poised for an outstanding year, not only in expanding market share for our current portfolio but also in achieving the key milestones required for the successful launch of our upcoming product pipeline."

"We are pleased to welcome Mike to the Aspira management team," said Dr. Sandra Milligan, Interim Chief Executive Officer of Aspira Women's Health. "Mike's commercial experience and deep understanding of the micro-cap, life sciences industry will be immediately beneficial to Aspira, and we look forward to his commercial expertise and guidance to help take us through our next phase of growth." 

Separately, Interim Chief Financial Officer John Kallassy will be leaving the Company on January 10, 2025, to pursue other business opportunities. In his place, the Company has retained Mr. James O'Brien as CFO advisor. Mr. O'Brien brings over 30 years of experience in the biotechnology, pharmaceutical, and medical device industries. Over the short term, he will assist the Company in strategic initiatives, business development, and financial matters.

Mr. O'Brien is the founder of Great Island Advisors LLC, a firm dedicated to leading and growing public and privately held businesses. Previously, he served as Chief Financial Officer of Faron Pharmaceuticals Ltd. (FARON), a clinical stage biotechnology company focused on oncology and immunotherapies. Mr. O'Brien also served as the inaugural Chief Financial Officer of Cognition Therapeutics, Inc. (CGTX), a clinical stage biopharmaceutical company which successfully completed an initial public offering in October 2021, raising $52 million. Earlier in his career, he held positions at pharmaceutical companies including Actavis PLC (now AbbVie, Inc. (ABBV)), the US subsidiary of Swiss company Nycomed Pharma S.A., which has since been acquired by Takeda Pharmaceutical Company Limited, and The Bristol Myers Squibb Company. He spent close to a decade at PricewaterhouseCoopers and is a certified public accountant (CPA) with a Bachelor of Accountancy degree from George Washington University and a Master of Business Administration degree from Fordham University.

Mike Buhle and Jim O'Brien will be joining interim CEO, Dr. Sandra Milligan for meetings during the JP Morgan Healthcare Conference week beginning on January 13th in San Francisco, CA.

About Aspira Women's Health Inc. 

Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-enabled tests to aid in the diagnosis of gynecologic diseases.    

OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the more than 1.2 million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery.     

Our in-development test pipeline will expand our ovarian cancer portfolio and address the need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests and expand the indicated population to screen women with a family history of ovarian cancer or a germline mutation. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying endometriosis independent of disease location or severity.

Forward-Looking Statements 

This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "designed to," "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including those factors identified as "Risk Factors" in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. 

Investor Relations Contact: 

Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com

SOURCE: Aspira Women's Health



View the original press release on accesswire.com

Get the next $AWH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AWH

DatePrice TargetRatingAnalyst
1/12/2022$4.00Overweight
Cantor Fitzgerald
More analyst ratings

$AWH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

    Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations.Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses. He brings hands-on leadership experience in clinical diagnostics specializing in precision medicine and patient outcomes in oncology, rare dise

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

    AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award

    AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related agreement. ARPA-H's Sprint for Women's Health was created to address critical unmet challenges in women's health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. As previously a

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$AWH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AWH
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$AWH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AWH
SEC Filings

See more

$AWH
Leadership Updates

Live Leadership Updates

See more
  • Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

    AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub

    AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors

    AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing several billion-dollar portfolios over his career. "We are pleased to welcome John to our Board of Directors," said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women's Health. "John brings a wealth of experience and a keen understanding of Wall Street, having been a successful money manager for the past

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$AWH
Financials

Live finance-specific insights

See more
  • Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results

    Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

    AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

    AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Monday, August 12, 2024Time: 4:30 p.m. ETToll Free:877-407-4018Webcast:Click HERE   A replay of the webcast will also be

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$AWH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more